Targeting the NF- κB pathway as a potential regulator of immune checkpoints in cancer immunotherapy

Cell Mol Life Sci. 2024 Feb 29;81(1):106. doi: 10.1007/s00018-023-05098-8.ABSTRACTAdvances in cancer immunotherapy over the last decade have led to the development of several agents that affect immune checkpoints. Inhibitory receptors expressed on T cells that negatively regulate the immune response include cytotoxic T‑lymphocyte antigen 4 (CTLA4) and programmed cell death protein 1 (PD1), which have been studied more than similar receptors. Inhibition of these proteins and other immune checkpoints can stimulate the immune system to attack cancer cells, and prevent the tumor from escaping the immune response. However, the administration of anti-PD1 and anti-CTLA4 antibodies has been associated with adverse inflammatory responses similar to autoimmune diseases. The current review discussed the role of the NF-κB pathway as a tumor promoter, and how it can govern inflammatory responses and affect various immune checkpoints. More precise knowledge about the communication between immune checkpoints and NF-κB pathways could increase the effectiveness of immunotherapy and reduce the adverse effects of checkpoint inhibitor therapy.PMID:38418707 | DOI:10.1007/s00018-023-05098-8

Source: Cellular and Molecular Life Sciences : CMLS - February 28, 2024 Category: Cytology Authors: Nasim Ebrahimi Al-Hasnawi Rasool Riyadh Abdulwahid Atena Mansouri Nasrin Karimi Rashid Jafardoust Bostani Sheida Beiranvand Samaneh Adelian Roya Khorram Reza Vafadar Michael R Hamblin Amir Reza Aref Source Type: research